BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 2020;20:1001-14. [PMID: 32724339 DOI: 10.3892/ol.2020.11685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Hong E, Chen XE, Mao J, Zhou JJ, Chen L, Xu JY, Tao W. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report. World J Clin Cases 2022;10:2836-43. [PMID: 35434119 DOI: 10.12998/wjcc.v10.i9.2836] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fang F, Yuan Q. Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C. Oncol Lett 2022;23:46. [PMID: 34976158 DOI: 10.3892/ol.2021.13164] [Reference Citation Analysis]
3 Li Y, Zhao X, Tian Y, Xiao X, Yan C, Shen H. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report. Front Genet 2022;13:949989. [DOI: 10.3389/fgene.2022.949989] [Reference Citation Analysis]
4 Tang M, Song C, Zhang Y, Xu X, Wang C, Zhang Z, Chen T. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib. Lipids Health Dis 2021;20:165. [PMID: 34801029 DOI: 10.1186/s12944-021-01596-5] [Reference Citation Analysis]
5 Liang C, Yu X, Xiong N, Zhang Z, Sun Z, Dong Y. Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway. Front Oncol 2020;10:615146. [PMID: 33659212 DOI: 10.3389/fonc.2020.615146] [Reference Citation Analysis]
6 Zhu Z, Jiang T, Suo H, Xu S, Zhang C, Ying G, Yan Z. Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways. Front Pharmacol 2021;12:712181. [PMID: 34421608 DOI: 10.3389/fphar.2021.712181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lengyel CG, Hussain S, Seeber A, Jamil Nidhamalddin S, Trapani D, Habeeb BS, Elfaham E, Mazher SA, Seid F, Khan SZ, El Bairi K, Odhiambo A, Altuna SC, Petrillo A. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target? Life (Basel) 2022;12:81. [PMID: 35054474 DOI: 10.3390/life12010081] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Imran M, Khan SA, Alshammari MK, Alreshidi MA, Alreshidi AA, Alghonaim RS, Alanazi FA, Alshehri S, Ghoneim MM, Shakeel F. Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions. Biomedicines 2021;9:1938. [PMID: 34944754 DOI: 10.3390/biomedicines9121938] [Reference Citation Analysis]
9 Yao W, Du X, Wang J, Wang X, Zhang P, Niu X. Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma. Onco Targets Ther 2022;15:669-79. [PMID: 35726279 DOI: 10.2147/OTT.S365506] [Reference Citation Analysis]
10 Liang L, Chen T, Ren T, Mao M, Wang K, Tang C, Xiao J, Jia H, Chen W, Wang Q, Li T. First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma. Cancer Manag Res 2022;14:103-6. [PMID: 35023973 DOI: 10.2147/CMAR.S344149] [Reference Citation Analysis]
11 Chen F, Peng H, Liu H, Peng L. Factors Influencing the Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer. International J of Pharmacology 2022;18:1071-8. [DOI: 10.3923/ijp.2022.1071.1078] [Reference Citation Analysis]
12 Wang P, Fang X, Yin T, Tian H, Yu J, Teng F. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study. Front Oncol 2021;11:628124. [PMID: 33791214 DOI: 10.3389/fonc.2021.628124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lu Y, Lin J, Duan M, Rui Y, Zheng H, Zhu L, Zhu X, Wei J. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway. Anal Cell Pathol (Amst) 2021;2021:5228713. [PMID: 34926131 DOI: 10.1155/2021/5228713] [Reference Citation Analysis]
14 Wang G, Beeraka NM, Xiao W, Zhang Y, Xue N, Chen G, Liu J, Liu Y. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC. Technol Cancer Res Treat 2022;21:15330338221080939. [PMID: 35235470 DOI: 10.1177/15330338221080939] [Reference Citation Analysis]
15 Huang Z, Su Q, Li W, Ren H, Huang H, Wang A. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma. J Genet Genomics 2021:S1673-8527(21)00201-0. [PMID: 34373220 DOI: 10.1016/j.jgg.2021.06.014] [Reference Citation Analysis]
16 Woods E, Le D, Jakka BK, Manne A. Changing Landscape of Systemic Therapy in Biliary Tract Cancer. Cancers (Basel) 2022;14:2137. [PMID: 35565266 DOI: 10.3390/cancers14092137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Li L, Zhang H, Xie Y, Su N, Su S, Zhang X, Cen W, Koundal D. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study. Computational and Mathematical Methods in Medicine 2022;2022:1-6. [DOI: 10.1155/2022/1475871] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hong E, Chen XE, Mao J, Zhou JJ, Chen L, Xu JY, Tao W. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report. World J Clin Cases 2022; 10(9): 2834-2841 [DOI: 10.12998/wjcc.v10.i9.2834] [Reference Citation Analysis]
19 Su Y, Cheng S, Qian J, Zhang M, Li T, Zhang Y, Diao C, Zhang L, Cheng R. Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations. Front Oncol 2021;11:626076. [PMID: 33842329 DOI: 10.3389/fonc.2021.626076] [Reference Citation Analysis]
20 Sun X, Zhang R, Xu J, Xie L, Guo W. First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial. Asian Pac J Trop Med 2022;15:266. [DOI: 10.4103/1995-7645.348155] [Reference Citation Analysis]
21 Lv B, Chen J, Liu XL. Anlotinib-Induced Hypertension: Current Concepts and Future Prospects. Curr Pharm Des 2021. [PMID: 34620054 DOI: 10.2174/1381612827666211006145141] [Reference Citation Analysis]
22 Qu N, Hui Z, Shen Z, Kan C, Hou N, Sun X, Han F. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development. Front Endocrinol 2022;13:873027. [DOI: 10.3389/fendo.2022.873027] [Reference Citation Analysis]
23 Kong T, Chen L, Zhao X, Duan F, Zhou H, Wang L, Liu D. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study. Invest New Drugs 2022. [PMID: 35788937 DOI: 10.1007/s10637-022-01279-7] [Reference Citation Analysis]
24 Jiang J, Ren Y, Xu C, Lin X. NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report. Diagn Pathol 2022;17:4. [PMID: 34996489 DOI: 10.1186/s13000-021-01188-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Jin Z, He Q, Zhu X, Zhu M, Wang Y, Wu XA, Lv Q, Xiang X. Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes. Basic Clin Pharmacol Toxicol 2022;130:592-605. [PMID: 35289081 DOI: 10.1111/bcpt.13721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lu S, Hong Y, Chen H, Wu L, Sun F, Wang J, Zhu J, Que Y, Zhang L, Zhen Z, Sun X, Huang J, Zhang Y. The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors. Front Pharmacol 2022;13:711704. [DOI: 10.3389/fphar.2022.711704] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhu H, Li G, Yin J, Zhang H, Da Y, Li L. Anlotinib attenuates experimental autoimmune encephalomyelitis mice model of multiple sclerosis via modulating the differentiation of Th17 and Treg cells. Immunopharmacol Immunotoxicol 2022;:1-9. [PMID: 35638564 DOI: 10.1080/08923973.2022.2071722] [Reference Citation Analysis]
28 Mou L, Tian X, Zhou B, Zhan Y, Chen J, Lu Y, Deng J, Deng Y, Wu Z, Li Q, Song Y, Zhang H, Chen J, Tian K, Ni Y, Pu Z. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Front Oncol 2021;11:752725. [PMID: 34707994 DOI: 10.3389/fonc.2021.752725] [Reference Citation Analysis]